Brief: Cingulate Announces Pricing Of $4 Mln Public Offering
Brief: Cingulate Announces Detailed Trial Results From Phase 3 Adult Efficacy And Safety Trial Of CTx-1301 For ADHD
Brief: Werth Family Investment Associates Converts $5.8 Million Of Debt Into Cingulate Equity At A Premium
Brief: Cingulate Presents Full Trial Results From Phase 3 Adult Efficacy And Safety Trial Of CTX-1301 For ADHD At Psych Congress 2023
Brief: Cingulate Inc Files For Offering Of 7.4 Million Shares Of Common Stock Together With Series A Warrants And Series B Warrants- SEC Filing
Brief: Cingulate Inc Files For Offering 8.06 Million Shares Of Common Stock Together With Series A Warrants And Series B Warrants
Brief: Cingulate Inc. Q2 net income USD -6.6 million
Brief: Cingulate Inc Says On July 28, Received Notice From Nasdaq Indicating That Co Not In Compliance With Minimum Bid Price Requirement
Brief: Cingulate Files For Offering Of Up To 6.5 Million Common Shares
U.S. STOCKS ON THE MOVE-Zillow Group, TransAlta, Everbridge
U.S. STOCKS ON THE MOVE-EBay, Newell Brands, Semler Scientific
U.S. STOCKS ON THE MOVE-VeriSign, Equitrans Midstream, Nutrien
Cingulate rises after positive late-stage data on ADHD drug
Brief: Cingulate Says Initiation Of Pediatric Phase 3 Studies To Commence In July And August
Cingulate up on completing trial of lead drug candidate
Brief: Cingulate Completes Phase 3 Adult Trial Of CTx-1301 (dexmethylphenidate) For ADHD
Brief: Cingulate - On May 16, Received Letter From Nasdaq
Brief: Cingulate Inc. Reports First Quarter 2023 Financial Results And Provides Clinical And Business Update
Brief: Cingulate Says Increased Maximum Offering Price Of Shares Of Co's Common Stock, Issuable Under Sales Agreement With H.C. Wainwright & Co., To $4.97 Million